. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Cancer Metastasis Rev. 2017 Sep;36(3):463–473. doi: 10.1007/s10555-017-9687-8

Table I.

EGFR-targeted Monoclonal Antibodies

Compound	Company	Description	Approval and Clinical Indications
Cetuximab Erbitux (IMC-C225)	ImClone Systems Incorporated Bristol-Myers Squibb Eli Lily Merck KGaA	Chimeric, murine antibody and human IgG1	2004: FDA approval for metastatic colorectal
			2006: FDA approval for use in combination with XRT for locally or regionally advanced HNSCC or as monotherapy for platinum refractory, recurrent, or metastatic HNSCC
			2009: FDA approval for KRAS wild type colorectal cancer
			2011: FDA approval for use as first-line treatment in combination with platinum based chemotherapeutics and 5-FU for recurrent local-regional or metastatic HNSCC
Panitumumab Vectibix (ABX-EGF)	Amgen Takeda	Humanized mAb	2006: FDA approval for metastatic CRC
			2007: European Medicines Agency approval for use in combination with FOLFIRI chemotherapy for metastatic colon cancer
			2008: Health Canada approval for refractory EGFR-expressive metastatic CRC with wild type KRAS
			2014: FDA approval in combination with FOLFOX for first line treatment of wild type KRAS CRC
Nimotuzumab	YM Biosciences	Humanized mAb	2006: Approval for HNSCC in India
			2008: Approval in combination with XRT for NPC in China
			Phase II and III studies for cancers including HNSCC, esophageal, gastric, CRC, and gliomas
Zalutumumab Genmab	Genmab MATOS Pharma	Human IgG1	Phase I, II, and III for HNSCC, NSCLC, and CRC
Duligotuzumab	Roche	Humanized dual EGFR/HER3 mAb	Phase I and II studies in HNSCC

CRC, colorectal cancer. FDA, Food and Drug Administration. FOLFOX, a chemotherapy combination of leucovorin, fluorouracil, and oxaliplatin. HNSCC, head and neck squamous cell carcinoma. NPC, nasopharyngeal carcinoma. XRT, radiotherapy.